Historical Valuation
BIOCYTOGEN-B (02315) is now in the Fair zone, suggesting that its current forward PS ratio of 13.65 is considered Fairly compared with the five-year average of -15.24. The fair price of BIOCYTOGEN-B (02315) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：35.90
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
BIOCYTOGEN-B (02315) has a current Price-to-Book (P/B) ratio of 14.39. Compared to its 3-year average P/B ratio of 6.43 , the current P/B ratio is approximately 123.74% higher. Relative to its 5-year average P/B ratio of 6.65, the current P/B ratio is about 116.42% higher. BIOCYTOGEN-B (02315) has a Forward Free Cash Flow (FCF) yield of approximately 1.60%. Compared to its 3-year average FCF yield of -1.98%, the current FCF yield is approximately -181.08% lower. Relative to its 5-year average FCF yield of -2.39% , the current FCF yield is about -167.16% lower.
P/B
Median3y
6.43
Median5y
6.65
FCF Yield
Median3y
-1.98
Median5y
-2.39
Performance Decomposition
AI Analysis for 02315
1Y
3Y
5Y
Market capitalization of 02315 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02315 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 02315 currently overvalued or undervalued?
BIOCYTOGEN-B (02315) is now in the Fair zone, suggesting that its current forward PS ratio of 13.65 is considered Fairly compared with the five-year average of -15.24. The fair price of BIOCYTOGEN-B (02315) is between to according to relative valuation methord.
What is BIOCYTOGEN-B (02315) fair value?
02315's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BIOCYTOGEN-B (02315) is between to according to relative valuation methord.
How does 02315's valuation metrics compare to the industry average?
The average P/S ratio for 02315's competitors is , providing a benchmark for relative valuation. BIOCYTOGEN-B Corp (02315) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for BIOCYTOGEN-B (02315) as of Jan 10 2026?
As of Jan 10 2026, BIOCYTOGEN-B (02315) has a P/B ratio of 14.39. This indicates that the market values 02315 at 14.39 times its book value.
What is the current FCF Yield for BIOCYTOGEN-B (02315) as of Jan 10 2026?
As of Jan 10 2026, BIOCYTOGEN-B (02315) has a FCF Yield of 1.60%. This means that for every dollar of BIOCYTOGEN-B’s market capitalization, the company generates 1.60 cents in free cash flow.
What is the current Forward P/E ratio for BIOCYTOGEN-B (02315) as of Jan 10 2026?
As of Jan 10 2026, BIOCYTOGEN-B (02315) has a Forward P/E ratio of 72.21. This means the market is willing to pay $72.21 for every dollar of BIOCYTOGEN-B’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BIOCYTOGEN-B (02315) as of Jan 10 2026?
As of Jan 10 2026, BIOCYTOGEN-B (02315) has a Forward P/S ratio of 13.65. This means the market is valuing 02315 at $13.65 for every dollar of expected revenue over the next 12 months.